0
Editor's Correspondence |

Ethnic, Racial, and Sex-Specific Factors Are Important in Cardiovascular Pharmacotherapeutics

Vincent J. Caracciolo, MD; Benjamin M. Shaefer, MD; Pamela Charney, MD
Arch Intern Med. 2002;162(21):2494. doi:.
Text Size: A A A
Published online

Extract

In recent years, attention has been focused on genetic polymorphisms as reported recently by Flockhart and Tanus-Santos.1 However, ethnic, racial, and sex-specific genetic factors may also lead to differences in cardiovascular pharmacotherapeutics and are not acknowledged in their current review.

Racial differences in CYP2D6 have been documented, which are also not included in the review by Flockhart and Tanus-Santos. CYP2D6 oxidizes several β-receptor antagonists, most notably metoprolol.2 Many CYP2D6 polymorphisms, conferring phenotypic differences in enzyme function, have been reported. Patients are described as extensive or poor metabolizers. Most alleles identified cause a loss of function or decreased function. Poor metabolizer phenotypes have been estimated at 1% in Chinese subjects compared with 7% in white subjects.3 During long-term oral administration of metoprolol to Chinese patients with poor metabolizer genotype CYP2D6 *10A, subjects demonstrated higher steady state level of metoprolol racemates.3 Some authors suggest that the poor metabolizer prevalence is why Asians and possibly whites may require lower doses of metoprolol for a significant clinical response. Other alleles lead to an increased metabolic activity by gene duplication described as an ultrarapid metabolizer phenotype. Gene duplication has been observed in Saudi Arabians and Ethiopians.4

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();